What Weltruza’s Approval Could Mean For Teva

On Friday, Teva announced FDA approval of Weltruza, a monthly injection of olanzapine for adults with schizophrenia. The FDA recorded its approval the previous day. Teva said it expected U.S. availability in the coming weeks.

Olanzapine is already used as a daily tablet. Weltruza releases the medicine gradually through an injection under the skin, given by a healthcare professional. For suitable patients who struggle to take a tablet every day, monthly treatment could make the routine easier.

That gives Teva a practical opportunity: offer an established medicine in a form that reduces some of the work involved in receiving treatment.

The FDA label for another injectable olanzapine product, Zyprexa Relprevv, requires at least three hours of observation after every injection in a certified healthcare setting. Its label warns about severe sedation or delirium, meaning serious confusion.

Teva says Weltruza requires no post injection monitoring. Removing that mandatory observation period could save patients and caregivers time. It could also reduce the staff time and space a clinic must set aside for each appointment. Those are concrete reasons a different delivery method might influence prescribing.

Starting Weltruza requires no loading doses, meaning extra initial doses to establish drug exposure, or oral supplementation alongside the injection. Clinicians must first establish that the patient can tolerate oral olanzapine.

The potential benefit is an easier treatment routine for both the patient and the clinic. Whether that changes prescribing and keeps patients returning is the next test.

Weight gain and sleepiness remain among Weltruza’s common adverse reactions. Its prescribing information calls for fasting blood sugar and blood fat testing at the beginning of treatment and periodically afterward. These concerns will still matter when clinicians and patients choose a medicine.

The observation requirement also needs careful reading. Teva’s safety information says it is unknown whether post injection delirium/sedation syndrome can occur with Weltruza. This syndrome can happen when too much olanzapine enters the bloodstream too quickly. The absence of a required observation period is not a guarantee that the risk is absent.

The label also carries a boxed warning about increased mortality in elderly patients with dementia related psychosis. Weltruza is not approved for that condition. Choosing appropriate patients and providing continuing clinical care remain central to its use.

Teva already sells Uzedy, an injectable form of a different antipsychotic medicine, risperidone. U.S. Uzedy revenue reached $77 million in the quarter ended June 30, 2026, up 43% from the same quarter of 2025. Teva therefore has commercial experience in this treatment area, although Weltruza will have its own adoption curve.

For Weltruza to generate sustained demand, several things must happen. A clinician selects the treatment. The patient obtains insurance coverage or another way to pay. The injection is administered, and the patient returns for later doses. Interest in a medicine becomes a durable business only when patients can receive and continue treatment.

That process takes time. On its October 9 investor call, management described obtaining Medicaid coverage state by state as a launch hurdle and said it did not expect significant Weltruza revenue in the first half of 2027. That is management’s expectation, rather than a reported sales result.

Then there is the question of how much Teva keeps. Sales deductions, manufacturing costs, launch support and partner payments all affect profit. Medincell, whose technology helps release the medicine gradually, says it is entitled to royalties in the mid to high single digits on worldwide Weltruza net sales. Those are payments tied to sales, so the technology partner shares in the product’s commercial success.

Broad access and continued treatment could make Weltruza a durable source of revenue. Difficulties obtaining coverage or side effects that cause patients to stop could limit that opportunity, even if the appointment itself is easier.

The useful evidence now is actual availability, insurance coverage, patients receiving their first injections and patients returning for later doses. Together, those measures would help show whether the delivery improvement is changing treatment decisions.

Teva has scheduled its third quarter results for November 3, 2026. That could provide an early commercial update, but approval came after the quarter ended. Commentary about the launch will likely be more informative than looking for Weltruza sales in that quarter’s results.

For a newer investor, this is a useful distinction: regulatory approval allows the commercial opportunity to move forward. Patient uptake, continued treatment and the profit Teva retains will determine how valuable that opportunity becomes.